ExodusPoint Capital Management LP Makes New Investment in Cencora, Inc. $COR

ExodusPoint Capital Management LP acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 48,814 shares of the company’s stock, valued at approximately $16,487,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after purchasing an additional 221,570 shares during the last quarter. State Street Corp raised its holdings in Cencora by 1.3% during the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after purchasing an additional 115,191 shares during the last quarter. Geode Capital Management LLC raised its holdings in Cencora by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after purchasing an additional 169,055 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Cencora by 6.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock worth $1,682,859,000 after purchasing an additional 304,760 shares during the last quarter. Finally, Boston Partners raised its holdings in Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after purchasing an additional 89,506 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of COR stock opened at $281.22 on Wednesday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock has a market cap of $54.71 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The stock has a 50-day moving average of $287.49 and a 200-day moving average of $326.05. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on COR. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Wells Fargo & Company lowered their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. William Blair began coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.